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Pharmaceutical careAbstract Background and objective: The promotion of medication adherence is considered as an
integral component of pharmaceutical care practice and patient healthcare. An approach which
focuses on the choice and dose of antiepileptic drug will have limited success without medication
adherence. This study sought to assess medication adherence for improvement among adolescents
who are suffering from epilepsy.
Methods: A total of 116 patients affected with idiopathic epilepsy and fulﬁlled the inclusion
criteria were recruited in the current study. Adherence to the treatment was evaluated during
patients’ hospitalization in the Department of Neurology at Riyadh National Hospital, Riyadh,
Saudi Arabia, between December 2011 and January 2014. The medication adherence has been
assessed during semi-structured interviews with each patient and/or his parents using a multiple
choice graded questionnaire.
Results: From the selected group of patients, only 94 patients (81.0%) fulﬁlled the inclusion cri-
teria within the study period. Thirty-six of respondents (38.3%) were non adherent to antiepileptic
treatment. No statistical differences were found between males and females regarding their ages, age
at diagnosis of epilepsy, mother age, epilepsy duration, family numbers, number of poor-adherents
or seizure frequency. The most important factors that were signiﬁcantly affecting patients’ adher-
ence to the prescribed medications were age of mother, family number, number of administered
drugs, the stability of parents’ marriage, family support, and seizure frequency as well as theypt and
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34 W.M. Gabr, M.E.E. Shamsregularity of the relationship between patients and their healthcare providers. Forgetfulness was the
most common cause of non-adherence among this group of patients followed by inability to obtain
medication and fear from side effects of drugs. Our results revealed also that the number of patients
who felt to be stigmatized is signiﬁcantly more in non-adherent group as compared to patients with
a strong sense of normality (P< 0.05). A positive relationship between adherence and the necessity
and beneﬁt scales at which patients have a stronger belief in the necessity of medication for control-
ling illness was associated with good adherence.
Conclusion: The assessment of medication adherence among epileptic patients should be a
routine part of the management process to improve the health care and quality of lives of those
patients.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Epilepsy is a neurological condition, which affects the nervous
system. Epilepsy is also known as a seizure disorder (England
et al., 2012). It is usually diagnosed after a person has had at
least two seizures that were not caused by some known medical
condition like alcohol withdrawal, extremely low blood sugar,
heart problems or some other medical condition (Berg et al.,
2013). Sometimes, according to the International League
Against Epilepsy, epilepsy can be diagnosed after one seizure,
if a person has a condition that places him/her at a high risk of
having another (Kaiboriboon et al., 2013). Epilepsy is the sec-
ond common disease among chronic nervous diseases next to
stroke (Ray et al., 2002) which affects approximately over 50
million patients worldwide (de Boer et al., 2008), with a prev-
alence rate ranging from 16 to 51 per 100,000 population in the
developed countries and 35–111 per 100,000 population in the
developing countries (Banerjee et al., 2009).
Epilepsy may promote limitations and restrain activities,
interfering with the occupational ability, professional goals
and social integration of patients (Gomes et al., 1998). It
increases morbidity and symptomatic epilepsy reduces life
expectancy by 18 years at maximum (Gaitatzis et al., 2004).
It continues to be a highly stigmatized and disabling chronic
condition (Paschal et al., 2014) requiring a lifelong process of
adherence to the prescriber’s instructions and drug regimens
(Michaud et al., 1991; Adams et al., 1997). Medication
adherence or the older term, drug compliance, is deﬁned as
the extent to which patients follow the instructions they are
given for prescribed treatments and persistence as the
duration of time from initiation to discontinuation of
therapy (Shams and Barakat, 2010). Medication non-
adherence includes delaying prescription ﬁlls, failing to ﬁll
prescriptions, cutting dosages, and reducing the frequency
of administration.
When treating an individual with epilepsy, there are several
factors that cannot be modiﬁed such as the age of onset, the
etiology of the seizures and the location of the epileptogenic
zone. There are also some factors that may be amenable to
an intervention to improve outcomes. An obvious consider-
ation for the clinician is the choice of medication to prescribe.
Despite medication, it has been found that seizures persist in
20–35% of cases (Devinsky, 1999). It is necessary therefore
to identify other ‘‘modiﬁable factors’’ which could lead to
improved seizure control if targeted effectively (Jones et al.,
2006). Current estimates of non-adherence in epilepsy are sim-
ilar to those in other chronic illnesses and range from 30% to50% and non adherence may be the most important cause of
poorly controlled epilepsy (Gomes et al., 1998).
The promotion of medication adherence is considered now-
adays as an important component of pharmaceutical care
practice (Shams and Barakat, 2010). Medication adherence
should be discussed regularly with the patient, and in particu-
lar when a treatment seems to fail (Jones et al., 2006). There
are several types of non adherence. Therapeutic or medication
non adherence which includes failure to have the prescription
dispensed or renewed, omission of doses, errors of dosage,
incorrect administration, errors in the time and frequency of
administration, and premature discontinuation of the drug
regimen. A second type of non-adherence is dietary/exercise
non-adherence in which the patient fails to follow the diet
and exercise recommendations. A third type is the appoint-
ment non adherence at which the patient fails to show up at
clinics for the scheduled check up (Hughes and Manns, 2000;
Shams and Barakat, 2010).
Several methods are used to measure therapeutic adher-
ence. Indirect methods, like self reports and interviews with
patient, are the simplest and most common methods for mea-
suring medication adherence (Girerd et al., 2001; Shams and
Barakat, 2010). Although medication adherence and factors
associated with it have been extensively studied, very little is
known about the factors associated with good medication
adherence among epileptic patients (Kyngas, 2001).
Non-adherence leads to considerable morbidity, mortality,
and avoidable health care costs. In epilepsy, non-adherence
leads to lack of control over seizures, recurrence, increased
absenteeism from work and, possibly, injury to oneself or to
others (Asawavichienjinda et al., 2003; Enriquez-Caceres and
Soto-Santillana, 2006).
For the previous reasons, we conducted this research study
to identify the different factors which could affect the medica-
tion adherence among adolescent epileptic patients, to investi-
gate factors that may reduce morbidity caused by recurrent
seizures, and to know how we can improve the medication
adherence among those patients for optimum therapy outcome
and enhancement of their quality of lives.
2. Materials and methods
2.1. Patients’ characteristics
From December 2011 to January 2014, total 116 patients
affected with idiopathic epilepsy were recruited in the current
research study. These patients were randomly selected from
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Riyadh, Saudi Arabia. Approval for this study was granted
by the scientiﬁc committee at Riyadh National Hospital and
with the Helsinki Declaration of 1975, as revised in 1983.
Informed consent was taken from the patients to participate
in this study. Patients were informed that personal information
will never be disclosed to a third party.
Inclusion criteria for all participants were:
 aged between 13 and 18 years,
 diagnosed with epilepsy for at least one year,
 administered at least one antiepileptic drug,
 with normal neurological and cognitive development,
 without other severe co-morbidities,
 consented to participate in the current study.
Age selection was based on the expectation that by the age
of thirteen, self-care responsibilities had been assumed by the
adolescents.
2.2. Assessment of medication adherence
A database of the selected patients who underwent one or
more semi-structured interviews was created in the hospital
outpatient clinics after signing an informed consent. The data
were collected by means of interview with the patients and/or
their parents, by using a questionnaire of known reliability and
validity to assess treatment adherence (Morisky et al., 1986).
Beliefs about illness (illness perception questionnaire, IPQ)
and treatment (beliefs about medicines questionnaire, BMQ)
were also measured. Patients’ histories were taken and they
were asked about the age of onset of epilepsy to calculate
the disease duration, recent seizure frequency, details of
prescribed antiepileptic drugs and feelings of stigma.
2.3. The Morisky Medication Adherence Scale
TheMorisky Medication Adherence Scale (MMAS) consists of
four items with a scoring scheme of ‘‘Yes’’ = 0 and ‘‘No’’ = 1.
The items are summed to give a range of scores from 0 to 4. The
four questions included in this scale are: (1) Do you ever forget
to take your medicine? (2) Do you ever have problems remem-
bering to take your medication? (3) When you feel better, do
you sometimes stop taking your (name of health condition)
medicine?) When you felt better, did you sometimes stop taking
your medicines? (4) Sometimes, if you felt worse, did you stop
taking your medicines? In our study, patients were considered
poor-adherent if they scored 1 or more.
2.4. Beliefs about medicines questionnaire, (BMQ)
This questionnaire was developed in the UK and published by
Horne and Weinman (1999) and comprises two parts (general
and speciﬁc sections). Subjects are asked the extent to which
they agree or disagree with the statement on a ﬁve-point Likert
scale, where 1 = strongly disagree, 2 = disagree, 3 = uncer-
tain, 4 = agree and 5 = strongly agree, to investigate the
participant’s opinion for each item. The questionnaire is
divided into two sections, measuring beliefs about medicines
in general and beliefs about a speciﬁed medication. In this eval-
uation, items in the speciﬁc section were worded to relate to‘antiepileptic drugs’, where personal beliefs about the necessity
of the medication for maintaining or improving health (5
items, e.g. ‘‘my health at present depends upon my antiepilep-
tic drugs’’) are balanced against concerns about the potential
adverse effects of taking it (5 items, e.g. ‘‘having to take my
antiepileptic drugs worries me’’). Total scores for the necessity
and concerns scales ranged from 5 to 25. Higher scores indi-
cate stronger beliefs (Horne et al., 1999). A necessity–concerns
differential is calculated as the difference between the necessity
and the concerns scales, with a possible range of 20 to +20.
This differential can be thought of as the cost–beneﬁt analysis
for each patient, for whom costs (concerns) are weighed
against their perceived beneﬁts (necessity beliefs) (Horne
et al., 1999). A positive differential score indicates stronger
necessity beliefs than concerns, and a negative score indicates
the contrary i.e., stronger concerns. The general section con-
sists of the overuse subscale (e.g. ‘‘doctors use too many med-
icines’’), the Harm-Beneﬁt Subscale (e.g. ‘‘medicines do more
harm than good’’). Only completed questionnaires were
included in the analyses. The scores for each item in a subscale
are summed to give a total score which ranges from 4 to 20 for
the Harm and Beneﬁt scale and ranged from 3 to 15 for the
Overuse Scale. The total score for each sub-scale was then
divided by the number of items in the scale. Higher scores indi-
cate stronger beliefs in the concepts represented by the scale.
2.5. Data management and statistical analysis
Computer software GraphPad InStat version 6.00, GraphPad
Software, San Diego, California, USA was used to analyze the
data obtained from the questionnaire. For descriptive statis-
tics, the frequency and percentage were calculated for qualita-
tive variables while the mean values ± standard deviation
(SD), and range were used for quantitative variables. For
comparison between two groups Student’s t-test was used.
For correlation, Pearson correlation test was used. Chi-square
test and contingency coefﬁcient test were used to analyze the
signiﬁcant correlations between adherence and the tested
factors. For certain two variables, when P value is less than
0.05, there is a statistically signiﬁcant relationship between
the two variables.3. Results
3.1. Patient’s characteristics
From a total of 116 patients who were clinically examined dur-
ing the study period in the Neurology Department at Riyadh
National Hospital, Riyadh, Saudi Arabia, only 94 patients
(81.0%) fulﬁlled the inclusion criteria within the study period.
The characteristics of the selected group of patients are sum-
marized in Table 1.
From all patients, only 38.3% (N= 36) of them were non
adherent to antiepileptic treatment. No statistical differences
were found between males and females regarding their ages,
age at diagnosis of epilepsy (age of the disease onset), mother
age, epilepsy duration, family numbers, number of poor-
adherents or seizure frequency (Table 1).
Epilepsy in 83% of the patients (N= 78) was generalized,
in 14.9% of them (N= 14) was partial while in 2.1%
(N= 2) was unclassiﬁed. The most common types of epilepsy
36 W.M. Gabr, M.E.E. Shamswere generalized tonic–clonic seizures (65%, N= 61), and to a
less extent myoclonic seizures (6.4%, N= 6), and tonic
seizures (4.2%, N= 4).
3.2. Disease management
Monotherapy was used to control the disease condition in
76.6% of the patients (N= 72). Valproic acid was the most
common prescribed drug to control epilepsy among those
patients (59.6%, N= 56) followed by carbamazepine
(12.8%, N= 12), and levetiracetam (4.3%, N= 4). A combi-
nation of two drugs was used in 17% of them (N= 16) while
6.3% of patients (N= 6) required more than two drugs to
control their conditions.
3.3. Characteristics of adherent and non-adherent epileptic
patients to medication
Characteristics of patients’ adherence toward antiepileptic
drugs were signiﬁcantly affected by many factors like age of
mother, family number, number of administered drugs, the
stability of parents’ marriage, family support, and seizure fre-
quency as well as the regularity of the relationship between
patients and their healthcare providers (medical support)
(Table 2). Medication adherence in patients with generalized
epilepsy did not differ signiﬁcantly from the patients with focal
epilepsy (P= 0.860). The commonest causes of non-adherence
in the patients sample are summarized in Fig. 1. Cultural
believes that the main cause of the convulsion may be due to
possession by external powers or Evil Spirit constitutes 8.4%
of non adherent patients. Our results revealed that patients felt
to be stigmatized are signiﬁcantly more in non-adherent group
as compared to patients with a strong sense of normality
(P< 0.05).
3.4. Beliefs about medicines questionnaire (BMQ)
Speciﬁc necessity and speciﬁc concerns scales, and the neces-
sity–concerns differential, are presented in Table 3. No gender
differences were identiﬁed. In calculations of the necessity–
concerns differential, 78 respondents reported positive scores,
meaning that their belief about the necessity of taking medica-
tion to control their illness was stronger than their concernsTable 1 Characteristics of participants (N= 94).
Number of patients (%)
Mean age (±SD)
Mean age at diagnosis of epilepsy in years (±SD)
Mean age of the mother (±SD)
Mean duration of epilepsy in years (±SD)
Mean family number (±SD)
Number (%) of non-adherents (P1 on Morisky)
Number (%) of adherents (=0 on Morisky)
Seizure frequency [Number of cases (%)] <once/month
>one/Month but <one/week
>one/week but <one/day
>one/day
*Statistically signiﬁcant (t-test) or Chi-square at P< 0.05.regarding medication. For sixteen of the respondents, the
necessity concerns differential score was negative.
Associations between the BMQ scale and adherence to
medication are found in Table 4. A statistically signiﬁcant rela-
tionship between speciﬁc necessity, speciﬁc concerns, the neces-
sity–concerns differential, and beneﬁt–harm scales with the
adherence to administered medications was observed. Stronger
concerns about adverse consequences of taking the prescribed
medication and fears from the possible medication harm in
non-adherent group were observed. A positive relationship
between adherence and the necessity and beneﬁt scales at
which patients with stronger belief in the necessity of medica-
tion for controlling illness was associated with good adherence
(Table 4).
4. Discussion
Medication adherence among adolescents who are suffering
from epilepsy disorder has been studied less extensively,
although patients’ adherence to medication poses difﬁcult
issues for all clinicians. Poor patients’ adherence is considered
as one of the major causes of non-responsiveness to antiepilep-
tic drug therapy (Kyngas, 2000). More than 95% adherence
may be necessary to adequately suppress the epileptic seizures.
This means missing one or more doses of a regimen per week
may be enough to cause treatment failure and trigger seizures
(Johnbull et al., 2011). For this reason we classify our patients
either adherent or non-adherent to their medications (All or
None Rule). All literature reported that factors which inﬂu-
ence patients ‘adherence to their medications are multiple
and complex’. For these reasons, the primary purpose of this
current research study was to assess factors inﬂuencing medi-
cation adherence among adolescent epileptic Arabic patients
who have different cultures, believes and daily habits to pro-
vide recommendations for improvement in their healthcare
and quality of lives.
In this current study, 61.7% of the patients (N= 58) were
adherent to their medications according to their self or paren-
tal reports (Table 1) but this percentage has to be improved. In
other research study which was carried out by Kyngas (2000),
only one-ﬁfth (22%) of the adolescents with epilepsy felt that
they are adherent to medication. On the other hand, the rate
of patient adherence measured by Liu et al. (2013) was
51.9% while it was only 41% in another study carried outTotal Male Female P value t-test
94 (100%) 44 (46.8%) 50 (53.2%)
14.96 (1.74) 14.68 (1.59) 15.20 (1.87) 0.32
8.72 (2.53) 8.59 (2.04) 8.84 (2.94) 0.74
38.32 (5.51) 38.91 (5.91) 37.80 (5.19) 0.50
6.23(2.20) 6.09 (2.20) 6.36 (2.23) 0.32
7.38 (1.62) 7.64 (1.76) 7.16 (1.49) 0.64
36 (100.0) 20 (55.5%) 16 (44.5%) Chi-square = 1.79 (P= 0.18)
58 (100.0) 24 (41.4) 34 (58.6)
48 (51.0) 22 (23.4) 26 (27.6) Chi-square = 1.356 (P= 0.715)
20 (21.4) 10 (10.7) 10 (10.7)
16 (17.0) 6 (6.3) 10 (10.7)
10 (10.6) 6 (6.3) 4 (4.3)
Figure 1 Causes of non-adherence to antiepileptic medications.
Table 2 Characteristics of adherent and non-adherent epileptic patients.
Adherent Non-adherent Test P value
Total number (N= 94, 100%) 58 (61.7) 36 (38.3)
Number of males (N= 44, 100%) 24 (54.5) 20 (45.5) Chi-square = 1.793 0.18
Number of females (N= 50, 100%) 34 (68.0) 16 (32.0)
Mean age (±SD) 14.93(1.77) 15.00(1.75) t= 0.130 0.89
Mean age (year) at diagnosis of epilepsy (±SD) 2.49(0.46) 2.66(0.63) t= 0.585 0.56
Mean duration of epilepsy in years (±SD) 2.32(0.43) 2.03(0.48) t= 0.571 0.57
Mean age of Mother (±SD) 36.76(5.64) 40.83(4.33) t= 2.619 <0.05*
Mean Family Number (±SD) 6.66(1.42) 8.56(1.20) t= 4.721 <0.05*
Family history of similar illness (%) 10 (38.5%) 16 (61.5%)
Patients with monotherapy [N (%)] 40 (71.4) 16 (28.6) Chi-square = 5.546 <0.05*
Patients with polypharmacy [N (%)] 18 (47.4) 20 (52.6)
Stable parent marriage [N (%)] 44 (68.8) 20 (31.2) Chi-square = 4.215 <0.05*
Unstable parent marriage [N (%)] 14 (46.6) 16 (53.4)
Patients with good family support 39 12 Chi-square = 10.290 <0.01*
Patients with poor family support 19 24
Seizure Frequency [number of cases (%)] <once/month 42 (44.7) 6 (6.3) Chi-square = 33.06 <0.0001**
>one/Month but < one/week 10 (10.6) 10 (10.6)
>one/week but < one/day 2 (2.1) 14 (14.9)
>one/day 4 (4.2) 6 (6.3)
Patients with regular medical support 37 (75.5) 12 (24.5) Chi-square = 8.259 <0.05*
Patients without regular medical support 21 (46.6) 24 (53.5)
* Statistically signiﬁcant (t-test) or Chi-square at P< 0.05,
** Statistically signiﬁcant (t-test) or Chi-square at P< 0.01.
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compliance rate in his sample of patients was satisfactory in
almost three-fourths (75%) of the patients with epilepsy. These
variation in rate of compliance between different studies may
reﬂect the differences in patient attitude toward the prescribed
drug due to different cultures, beliefs, education, physician
approach to the patient with epilepsy or the degree of medical
and parental support.
The effect of gender as an important contributing factor
affecting the medication adherence was studied. No statisticalTable 3 A comparison in the mean of beliefs about medicines ques
Total
Necessity median 18 (13–25)
Concern median 11 (5–22)
Necessity–concerns diﬀerential score 8 (7–17)
Overuse median 9 (3–15)
Harm median 14 (4–19)
Beneﬁt median 12 (5–20)differences were found between both genders regarding their
ages, age of the disease onset, mother age, epilepsy duration,
family numbers, and seizure frequency or even in the adher-
ence to their medications (Table 1). These results are in agree-
ment with those carried out by Johnbull et al. (2011) who also
found that the gender does not affect adherence rate. Liu et al.
(2013) also concluded in other research study that there were
no demographic differences based on gender between adherent
and non- adherent patients which support our ﬁndings.
Other factors that may have a role on the rate of patient
adherence to antiepileptic drugs were also studied. The age
of disease onset and duration of the disease did not have a sig-
niﬁcant correlation with the rate of adherence among our
patients. In contrast, Kyngas (2000) found that the duration
of the disease is signiﬁcantly related to patient adherence.
Maternal age was signiﬁcantly higher in non-adherent
patients compared to adherent ones (P< 0.05). Family size
was also found to play a signiﬁcant negative role on patient
adherence to their medications (P< 0.05). Patients with posi-
tive family history of epilepsy were more non-adherent than
patients with negative family history (61.5% versus 38.5%).
Complex treatment is believed to threaten patient’s adher-
ence (Shams and Barakat, 2010). This study revealed thattionnaire scores (BMQ) in both sexes.
Male Female P value
18.5 (15–25) 18(13–23) 0.140
12 (5–22.) 10 (7–22) 0.327
7.5 (4–17.) 9 (7–16) 0.960
9 (3–14) 10 (5–15) 0.214
12.5 (4–19) 15 (10–19) 0.055
14.5 (8–20) 12 (5–18) 0.097
Table 4 Comparison between adherent and non-adherent groups of patients regarding BMQ.
Adherent group Non-adherent group Statistical test
Necessity median 20 (16–25) 15.5 (13–21) Z= 4.450 P< 0.01
Concern median 9 (5–15) 15.5 (13–22) Z= 5.570 P< 0.01
Necessity–concerns diﬀerential score 11 (2–17) 1 (7–8) Z= -5.552 P< 0.01
Overuse median 8 (3–12) 12 (9–15) Z= 5.281 P< 0.01
Harm median 12 (3–16) 16 (11–19) Z= 4.290 P< 0.01
Beneﬁt median 16 (8–20) 10 (5–15) Z= 4.202 P< 0.01
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ent than patient treated with polypharmacy (P< 0.05). This
is in agreement with the ﬁndings of another researcher who
found that the medication adherence was affected by the com-
plexity of the treatment at which taking many pills at different
times can lead patients to miss doses (Johnbull et al. (2011)).
On the other hand, Sweileh et al. (2011) stated that there
was no signiﬁcant difference in the rate of adherence between
patients on monotherapy and those on polypharmacy. The lat-
ter study was carried out at Al-Makhfya Governmental Out-
patient Center in Nablus, Palestine and all ages are included
in the research study but not only for adolescent which may
explain the result differences.
The frequency of seizure did not differ signiﬁcantly between
men and women (Table 1), but differed signiﬁcantly between
adherent and non-adherent groups (P< 0.0001). There was
an increase in the frequency of seizure among non-adherent
patients and this may be attributed to their incompliance with
the prescribed medications (Table 2). In addition, patients liv-
ing in family with stable marriage were signiﬁcantly more
adherent (P< 0.05) than patients with broken family such
as divorce, widow or separated parents and consequently are
living with only one parent.
The parent, other family member and friend support is con-
sidered as the corner stone to the medication adherence among
adolescents with epilepsy (Chigier, 1992; Desai et al., 1998).
Parental strategies found to be effective include planning of
self-care with adolescents, giving regular positive feedback,
and providing other rewards to promote medication adher-
ence. Family members and friends are important people to
whom adolescents want to talk (Hauser et al., 1993;
Woodgate, 1998). Our results showed that patients having
good family support were signiﬁcantly more adherent
(P< 0.01) compared to patients complaining of lack of family
support (Table 2). The same conclusion was reached by
Kyngas (2000) who stated that family support explained the
good compliance in his studied group of patients.
A healthy relationship is based on patients’ trust in pre-
scribers and empathy from the physicians, pharmacists and
nurses. Studies have found that adherence to medication is
good when healthcare providers are emotionally supportive,
giving reassurance or respect, and treating patients as an equal
partner (Chigier, 1992; Hauser et al., 1993; Kyngas, 2000;
Lawson et al., 2005). These studies stress the importance of
enabling patients to see their doctors and clinical pharmacists
regularly and to talk about epilepsy and explaining how to live
with it. Our results showed that patients with satisfactory reg-
ular medical relationship, supervision and support were signif-
icantly more adherent to their medication than patients feeling
not enough support from their health providers (P< 0.05).Liu et al. (2013) also found that the cause of non-adherence
in 9.5% of his patients’ group was bad patient–prescriber
relationship.
The reasons for non-adherence were found to include dis-
comfort resulting from treatment, expense of treatment, deci-
sions based on personal judgments about the effectiveness of
the proposed treatment, maladaptive coping styles (e.g., denial
of illness), or mental disorders (Blackwell, 2000; Kyngas,
2000). Forgetfulness was the most common cause of non-
adherence among this group of patients followed by inability
to obtain medication and then fear from side effects of drugs
(drowsiness, gastro-intestinal upset) or negative attitude
toward medication as explained in Fig. 1.These results are sup-
ported by the ﬁndings in other research studies. For example,
Liu et al. (2013), found that the primary reason for non-adher-
ence was forgetfulness in 69.6% of his studied group of
patients while Johnbull et al. (2011) observed that the cause
of non-adherence was forgetfulness in more than 40% of his
cases. In addition, Paschal et al. (2014) concluded that ‘‘forget-
fulness’’ was the primary reason for non-adherence in his stud-
ied group of patients.
The role possibly played by the stigma of epilepsy in
patients’ adherence to medication is unclear (Buck et al.,
1999; Austin et al., 2004). Dell deﬁned stigma as a distinctive
feature in an individual and the devaluation society places
on that difference. Stigma felt by people with epilepsy was
more profound in some countries than in others. Stigmatiza-
tion is most effective if the stigmatized person holds the same
belief as the society, as it often occurs in people with epilepsy
(Dell, 2014). In adolescents with epilepsy, stigma is a complex
concept to investigate because it involves personal attitudes
and beliefs, elements of secrecy and disclosure management,
and inﬂuences from the social environment (DiIorio et al.,
2003). It was obvious from our results that patients felt to be
stigmatized were signiﬁcantly more non-adherent as compared
to patients with a strong sense of normality (P-value < 0.05).
Buck et al. (1997), DiIorio et al. (2003) and Johnbull et al.
(2011) found also that participants reporting higher levels of
perceived stigma also reported lower levels of adherence.
Patients’ beliefs about their illness and the effectiveness of
medication are predictive of their adherence and the control
of seizure (Buck et al., 1997; Miner et al., 2013). Good motiva-
tion with a positive attitude toward disease and treatment, no
fear of complications and no fear of seizures explain good
adherence (Kyngas, 2000). The effect of patient beliefs on med-
ication adherence was studied in this current research study. It
was evident that there was an increase in adherence with stron-
ger beliefs in necessity of treatment and with low concern
beliefs as shown in Table 3. Patients with positive necessity–
concerns differential scores were more adherent compared to
Adherence to medication among outpatient adolescents with epilepsy 39patients with negative scores. In addition, patients who
believed that antiepileptic drugs beneﬁt more than harm were
signiﬁcantly more adherent (Tables 3 and 4). This is congruent
with the results obtained by Jones et al. (2006) who found that
epileptic patients, who had a greater belief in the need for
medication, were signiﬁcantly more adherent than those with
uncontrolled epilepsy.
5. Conclusion
Our study population of patients with epilepsy has demon-
strated that adherence to medications has to be improved.
Living with epilepsy is challenging because of its complex
bio-psychosocial characteristics. Diagnosis of epilepsy and
pharmacological treatment is not enough for epilepsy manage-
ment. Assessment of medication adherence among epileptic
patients should be a routine part of the management process.
Healthcare providers have to ﬁnd out all factors connected
to each adolescent’s adherence and try to modify them in
an individualized form and not as a package suitable for
all. Parental strategies found to be effective include planning
of self-care with adolescents, giving regular positive feedback,
and providing other rewards to promote medication
adherence.
Adolescents need frequent support, encouragement, and
positive feedback. Supportive care is much more important
than controlling relationships between adolescents, their
parents, and health care staff to improve their adherence to
medications. In addition, healthcare providers should continu-
ously evaluate the role of the family and patient feeling and
beliefs. Further studies are needed to evaluate the effect of
medication adherence and psychological care on seizure
control.
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